Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Development Officer | November 25, 2024 | November 28, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protagonist Therapeutics, Inc
Report date November 25, 2024 · Filed November 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 229,611 |
Reported balance
After 2024-11-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-11-25 · Exercise / conversion · Acquired 45,000 · Balance 229,611 F1: Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 274,611 |
Reported balance
After 2024-11-25 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-11-25 · Exercise / conversion · Acquired 45,000 · Balance 274,611 |
| Common StockSEC Table I · non-derivative | Direct | 359,611 |
Reported balance
After 2024-11-25 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-11-25 · Exercise / conversion · Acquired 85,000 · Balance 359,611 |
| Common StockSEC Table I · non-derivative | Direct | 256,174 |
Reported balance
After 2024-11-25 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2024-11-25 · Sale · Disposed 103,437 · Balance 256,174 F2: Sale to cover the exercise price of the options. F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 286,174 |
Reported balance
After 2024-11-26 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2024-11-26 · Exercise / conversion · Acquired 30,000 · Balance 286,174 |
| Common StockSEC Table I · non-derivative | Direct | 266,983 |
Reported balance
After 2024-11-26 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2024-11-26 · Sale · Disposed 19,191 · Balance 266,983 F2: Sale to cover the exercise price of the options. F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 267,433 |
Reported balance
After 2024-11-26 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2024-11-26 · Exercise / conversion · Acquired 450 · Balance 267,433 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2029-01-14 | Direct | 0 |
Reported balance
After 2024-11-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-25 · Exercise / conversion · Disposed 45,000 · Balance 0 F5: These stock options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.02 · Expires 2029-02-27 | Direct | 0 |
Reported balance
After 2024-11-25 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-25 · Exercise / conversion · Disposed 45,000 · Balance 0 F5: These stock options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2030-02-27 | Direct | 0 |
Reported balance
After 2024-11-25 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-11-25 · Exercise / conversion · Disposed 85,000 · Balance 0 F5: These stock options are fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2033-01-15 | Direct | 93,750 |
Reported balance
After 2024-11-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-11-26 · Exercise / conversion · Disposed 30,000 · Balance 93,750 F6: The stock option vests in 48 equal monthly installments following the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.17 · Expires 2033-01-15 | Direct | 93,300 |
Reported balance
After 2024-11-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-11-26 · Exercise / conversion · Disposed 450 · Balance 93,300 F6: The stock option vests in 48 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024.
F2: Sale to cover the exercise price of the options.
F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5: These stock options are fully vested.
F6: The stock option vests in 48 equal monthly installments following the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 450 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 12 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,300 Underlying: Common Stock · 450 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 11 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 30,000 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 450 | $12.17 | $5,476.50 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 7 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 19,191 | $45.50 | $873,190.50 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 6 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,983 F2 · kind: Sale to cover the exercise price of the options. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 30,000 | $12.17 | $365,100.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 5 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 10 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,000 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 9 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2029-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 8 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2029-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 103,437 | $46.04 | $4,762,239.48 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 4 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,174 F2 · kind: Sale to cover the exercise price of the options. F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.63 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 85,000 | $7.80 | $663,000.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 3 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 45,000 | $8.02 | $360,900.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2024 Filed Nov 28, 2024 00:09 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 45,000 | $7.38 | $332,100.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 1,326 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2024. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 4,282 | $29.53 | $126,447.46 |
DisclosureSEC source: 0001104659-24-028886 · tm247552-1_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,285 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 12,000 restricted stock units on February 26, 2024. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001104659-24-003435 · tm243091-1_4seq1.xml · derivative · entry 3 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 5,000 shares Expires 2029-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | SaleCommon Stock | 5,000 | $25.00 | $125,000.00 |
DisclosureSEC source: 0001104659-24-003435 · tm243091-1_4seq1.xml · nonDerivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,567 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 25, 2023. Read SEC document |
| January 09, 2024 Filed Jan 12, 2024 01:00 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 5,000 | $7.38 | $36,900.00 |
DisclosureSEC source: 0001104659-24-003435 · tm243091-1_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001495 · tm241954-7_4seq1.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2034-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:15 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 19,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001495 · tm241954-7_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,567 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 20:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001104659-23-110803 · tm2328975-1_4seq1.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 20:31 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 20,000 | $7.38 | $147,600.00 |
DisclosureSEC source: 0001104659-23-110803 · tm2328975-1_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 280 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:51 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 4,150 | $26.07 | $108,190.50 |
DisclosureSEC source: 0001104659-23-067691 · tm2317724-3_4seq1.xml · nonDerivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,037 F4 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs. F2 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:51 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067691 · tm2317724-3_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,187 F1 · shares: Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives. F2 · balance_after: The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date. F3 · balance_after: Includes an aggregate of 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2023. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:56 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 123,750 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004730 · tm233829-8_4seq1.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 123,750 shares Expires 2033-01-15 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 00:56 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 20,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004730 · tm233829-8_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,187 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on January 15, 2024, 2025 and 2026. F2 · balance_after: Includes 1 share acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2022. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 01:42 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001104659-22-050560 · tm2212815-5_4seq1.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests over a four-year period, with 1/4th of the shares subject to the option vesting on January 15, 2020, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
| April 26, 2022 Filed Apr 27, 2022 01:42 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 40,000 | $7.38 | $295,200.00 |
DisclosureSEC source: 0001104659-22-050560 · tm2212815-5_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 554 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2022. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 01:40 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Tax withholdingCommon Stock | 649 | $24.28 | $15,757.72 |
DisclosureSEC source: 0001104659-22-029522 · tm228264-3_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,007 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 1,875 vested restricted stock units on February 28, 2022. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $28.73 | $0.00 |
DisclosureSEC source: 0001104659-22-024838 · tm227111-2_4seq1.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-02-14 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:24 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-024838 · tm227111-2_4seq1.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,656 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025. F2 · balance_after: Includes an aggregate of 1,169 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $23.57 | $0.00 |
DisclosureSEC source: 0001209191-21-014967 · doc4.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common · 80,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014967 · doc4.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,987 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. F2 · balance_after: Includes an aggregate of 2,487 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2020 and September 9, 2020. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 22:44 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-014088 · doc4.xml · derivative · entry 1 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| December 03, 2019 Filed Dec 3, 2019 23:32 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | PurchaseCommon Stock | 30,000 | $5.13 | $153,900.00 |
DisclosureSEC source: 0001209191-19-058839 · doc4.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · EVP Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.99 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2019. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001209191-19-015926 · doc4.xml · derivative · entry 2 Gupta Suneel · CIK 0001763923 · EVP Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-02-27 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015926 · doc4.xml · nonDerivative · entry 1 Gupta Suneel · CIK 0001763923 · EVP Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. Read SEC document |
| January 15, 2019 Filed Jan 16, 2019 23:42 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0001209191-19-003994 · doc4.xml · derivative · entry 1 Gupta Suneel · CIK 0001763923 · EVP Clinical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2029-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date, and 1/36th of the remaining shares subject to the option vesting each month, subject to the Reporting Person continuing to be a service provider of the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.